Detalhe da pesquisa
1.
SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
Proc Natl Acad Sci U S A
; 118(6)2021 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33536335
2.
MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival.
Proc Natl Acad Sci U S A
; 116(10): 4508-4517, 2019 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30709910
3.
High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
J Biol Chem
; 293(35): 13750-13765, 2018 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29945974
4.
Identification of therapeutic targets applicable to clinical strategies in ovarian cancer.
BMC Cancer
; 16: 678, 2016 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27558154
5.
Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.
Breast Cancer Res
; 16(2): R41, 2014 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24745479
6.
SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243.
Cancer Res
; 81(11): 3067-3078, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33863777
7.
BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1).
Oncotarget
; 8(31): 51402-51415, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28881656
8.
Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.
Cancer Lett
; 354(2): 336-47, 2014 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-25193464